11 research outputs found
Hormonoterapia primaria en mujeres añosas con cáncer de mama localizado hormonosensible
Se analizó de forma retrospectiva una serie de pacientes con una edad mediana de 79 años con cáncer de mama localizado, con receptor de estrógeno positivo tratadas con hormonoterapia primaria. Tras recibir el tratamiento primario las pacientes candidatas se sometían a cirugía. La respuesta clínica fue de un 63.6%. La mediana de tiempo a progresión fue de 94 meses y la mediana de la supervivencia global no se alcanzó, siendo la media de 123 meses. Se evaluó el impacto del tratamiento quirúrgico en estos resultados, no objetivándose diferencias estadísticamente significativas. La hormonoterapia exclusiva en casos seleccionados es efectiva y seguraEs va analitzar de forma retrospectiva una sèrie de pacients amb una edat mitjana de 79 anys amb càncer de mama localitzat, amb receptor d'estrogen positiu tractades amb hormonoteràpia primària. Després de rebre el tractament primari les pacients candidates es van sotmetre a cirurgia. La resposta clínica va ser del 63.6%. La mitjana de temps a progressió va ser de 94 mesos i la mitjana de la supervivència global no es va assolir, essent la mitja de 123 mesos. Es va avaluar l'impacte de la cirurgia en aquests resultats, sense trobar-se diferències estadísticament significatives. La hormonoteràpia exclusiva en casos seleccionats és efectiva i segura
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a restrospective cohort study in Catalonia, Spain.
AIMS: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia. MATERIALS AND METHODS: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors. RESULTS: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018-0.267). Patients aged 50-74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy. CONCLUSIONS: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecular biology, tumor microenvironment, and mechanisms of drug resistance in breast cancer, we designed this window-of-opportunity study with the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402). Trial Design: Based on these data, a prospective, multicenter, single-arm, window-of-opportunity study was designed to evaluate the biological effect of patritumab deruxtecan in the treatment of naïve patients with HR-positive/HER2-negative early breast cancer whose primary tumors are ≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The primary endpoint is a CelTIL score after one single dose. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Background: Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy in a phase III trial. Patients and methods: PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitor (AI)-resistant MBC were included in two consecutive cohorts. In cohort 1, patients were randomised 1 : 1 to palbociclib plus exemestane or capecitabine. On discovering new evidence about estrogen receptor-1 (ESR1) mutations inducing resistance to AIs, the trial was amended to include cohort 2, in which patients were randomised 1 : 1 between palbociclib plus fulvestrant and capecitabine. The stratification criteria were disease site, prior sensitivity to ET, prior chemotherapy for MBC, and country of origin. Co-primary endpoints were progression-free survival (PFS) in cohort 2 and in wild-type ESR1 patients (cohort 1 + cohort 2). ESR1 hotspot mutations were analysed in baseline circulating tumour DNA. Results: From March 2014 to July 2018, 296 and 305 patients were included in cohort 1 and cohort 2, respectively. Palbociclib plus ET was not superior to capecitabine in both cohort 2 [median PFS: 7.5 versus 10.0 months; adjusted hazard ratio (aHR): 1.13; 95% confidence interval (CI): 0.85-1.50] and wild-type ESR1 patients (median PFS: 8.0 versus 10.6 months; aHR: 1.11; 95% CI: 0.87-1.41). The most frequent grade 3-4 toxicities with palbociclib plus exemestane, palbociclib plus fulvestrant and capecitabine, respectively, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot syndrome (0%, 0% and 23.5%), and diarrhoea (1.3%, 1.3% and 7.6%). Palbociclib plus ET offered better quality of life (aHR for time to deterioration of global health status: 0.67; 95% CI: 0.53-0.85). Conclusions: There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life
Factores pronósticos y predictivos de respuesta a la quimioterapia neoadyuvante con antraciclinas en una serie de cáncer de mama
El cáncer de mama es el cáncer más frecuente en mujeres de todo el mundo. El tratamiento neoadyuvante se introdujo en casos de enfermedad localmente avanzada; sin embargo, con el fin de incrementar el número de cirugías conservadoras, su uso se ha ido ampliando a estadios más precoces. El presente trabajo incluye el análisis retrospectivo de 86 casos de pacientes diagnosticadas de neoplasia de mama, tratadas de forma neoadyuvante de acuerdo con la decisión de la unidad funcional de mama del centro. Todas las pacientes recibieron quimioterapia neoadyuvante con un esquema de combinación de Fluorouracilo, Epirubicina y Ciclofosfamida. El tratamiento quimioterápico se asocia a numerosos e invalidantes efectos secundarios, conocer factores predictivos de la respuesta a la quimioterapia, nos permitiría tratar a aquellas pacientes que obtienen un mayor beneficio de la misma, evitando el tratamiento del resto.
En el trabajo se realizó el análisis inmunohistoquímico del estado de los receptores de estrógenos, los receptores de progesterona, HER-2, Vimentina, Citokeratinas 5/6 y de Ki67 y su correlación con las respuesta, el tiempo a la progresión y la supervivencia.
Por otra parte, a partir de la determinación inmunohistoquímica de los receptores de estrógenos y progesterona, HER-2, y ki67; se estableció la clasificación de los tumores en luminales A, luminales B, triple negativo y HER-2 positivo; evaluándose el valor pronóstico de esta clasificación y su valor predictivo de respuesta a la quimioterapia.
Huntingtin interacting protein 1 (HIP1), es una proteína de unión al lípido inositol y a clathrina, que interactúa con las proteínas de unión a actina, es considerada el primer componente de la maquinaria de endocitosis, jugando un papel fundamental en el tráfico de clathrina. En los últimos años, alteraciones de la regulación de la endocitosis, se han asociado con tumores. La modificación de las vías de endocitosis debido a la alteración de HIP1, podría por tanto afectar a diferentes procesos en la progresión a cáncer, así como en la respuesta a la quimioterapia de la enfermedad. En el presente trabajo, se analiza la expresión inmunohistoquímica de HIP1 y su relación con la respuesta a la quimioterapia, el tiempo a la progresión y la supervivencia.
Breast cancer susceptibility gene 1 (BRCA1), un gen que forma parte del homologous recombination repair, tiene un papel fundamental en la reparación del DNA, la regulación del ciclo celular, el control transcripcional, la ubicuitinación y la apoptosis. Se ha hipotetizado en anteriores trabajos que niveles bajos de mRNA de BRCA1 podrían predecir una mejor respuesta a agentes quimioterápicos cuyo mecanismo de acción se base en producir alteraciones del DNA, como las antraciclinas o los derivados del platino; y sin embargo peor respuesta a agentes como los taxanos. En nuestra experiencia se evaluaron los niveles de mRNA de BRCA1, así como su relación con la respuesta el tiempo a la progresión y la supervivencia de la serieBreast cancer is the most common cancer in women worldwide. Neoadjuvant treatment was introduced in cases of locally advanced disease, but in order to increase the number of conservative surgeries, use of neoadjuvant chemotherapy has been extended to earlier stages. This work includes retrospective analysis of 86 cases of patients treated with neoadjuvant chemotherapy according to the decision of the center’s Functional Unit of Breast Cancer. All patients received neoadjuvant chemotherapy with a combination schedule of fluorouracil, epirubicin and cyclophosphamide. Chemotherapy is associated with multiple disabling side effects, knowing predictors of response to chemotherapy, we would treat those patients who derive most benefit from it, avoiding the treatment of the rest.
We performed immunohistochemical analysis of the estrogen receptor, progesterone receptor, HER-2,Vimentin, cytokeratins 5/6 and Ki6. We correlated results with response, time to progression and survival.
Moreover, from the immunohistochemical determination of estrogen and progesterone receptor, HER-2 and Ki67, tumors were classified in luminal A, luminal B, triple negative and HER-2 positive; and assessed the prognostic and predictive value of this classification.
Huntingtin Interacting Protein 1 (HIP1) is a lipid-binding protein and clathrina inositol, which interacts with the actin-binding proteins, is considered the first component of the endocytosis machinery, playing an important role in trafficking of clathrina. In recent years, deregulation of endocytosis, have been associated with tumors. The change in the process of endocytosis due to alteration of HIP1, could therefore affect different processes in cancer progression and the response to chemotherapy. In this work we analyze the immunohistochemical expression of HIP1 and its relationship to chemotherapy response, time to progression and survival.
Breast cancer susceptibility gene 1 (BRCA1), a gene that is part of the homologous recombination repair, has a role in DNA repair, cell cycle regulation, transcriptional control, the ubiquitination and apoptosis. It has been hypothesized in previous work that low levels of BRCA1 mRNA may predict a better response to chemotherapeutic agents whose mechanism is based on producing DNA alterations, such as anthracyclines or platinum compounds, and yet worse response to agents as taxanes. In our work we evaluated BRCA1 mRNA levels and their relation to the response to chemotherapy, time to progression and survival
Factores pronósticos y predictivos de respuesta a la quimioterapia neoadyuvante con antraciclinas en una serie de cáncer de mama
El cáncer de mama es el cáncer más frecuente en mujeres de todo el mundo. El tratamiento neoadyuvante se introdujo en casos de enfermedad localmente avanzada; sin embargo, con el fin de incrementar el número de cirugías conservadoras, su uso se ha ido ampliando a estadios más precoces. El presente trabajo incluye el análisis retrospectivo de 86 casos de pacientes diagnosticadas de neoplasia de mama, tratadas de forma neoadyuvante de acuerdo con la decisión de la unidad funcional de mama del centro. Todas las pacientes recibieron quimioterapia neoadyuvante con un esquema de combinación de Fluorouracilo, Epirubicina y Ciclofosfamida. El tratamiento quimioterápico se asocia a numerosos e invalidantes efectos secundarios, conocer factores predictivos de la respuesta a la quimioterapia, nos permitiría tratar a aquellas pacientes que obtienen un mayor beneficio de la misma, evitando el tratamiento del resto. En el trabajo se realizó el análisis inmunohistoquímico del estado de los receptores de estrógenos, los receptores de progesterona, HER-2, Vimentina, Citokeratinas 5/6 y de Ki67 y su correlación con las respuesta, el tiempo a la progresión y la supervivencia. Por otra parte, a partir de la determinación inmunohistoquímica de los receptores de estrógenos y progesterona, HER-2, y ki67; se estableció la clasificación de los tumores en luminales A, luminales B, triple negativo y HER-2 positivo; evaluándose el valor pronóstico de esta clasificación y su valor predictivo de respuesta a la quimioterapia. Huntingtin interacting protein 1 (HIP1), es una proteína de unión al lípido inositol y a clathrina, que interactúa con las proteínas de unión a actina, es considerada el primer componente de la maquinaria de endocitosis, jugando un papel fundamental en el tráfico de clathrina. En los últimos años, alteraciones de la regulación de la endocitosis, se han asociado con tumores. La modificación de las vías de endocitosis debido a la alteración de HIP1, podría por tanto afectar a diferentes procesos en la progresión a cáncer, así como en la respuesta a la quimioterapia de la enfermedad. En el presente trabajo, se analiza la expresión inmunohistoquímica de HIP1 y su relación con la respuesta a la quimioterapia, el tiempo a la progresión y la supervivencia. Breast cancer susceptibility gene 1 (BRCA1), un gen que forma parte del homologous recombination repair, tiene un papel fundamental en la reparación del DNA, la regulación del ciclo celular, el control transcripcional, la ubicuitinación y la apoptosis. Se ha hipotetizado en anteriores trabajos que niveles bajos de mRNA de BRCA1 podrían predecir una mejor respuesta a agentes quimioterápicos cuyo mecanismo de acción se base en producir alteraciones del DNA, como las antraciclinas o los derivados del platino; y sin embargo peor respuesta a agentes como los taxanos. En nuestra experiencia se evaluaron los niveles de mRNA de BRCA1, así como su relación con la respuesta el tiempo a la progresión y la supervivencia de la serieBreast cancer is the most common cancer in women worldwide. Neoadjuvant treatment was introduced in cases of locally advanced disease, but in order to increase the number of conservative surgeries, use of neoadjuvant chemotherapy has been extended to earlier stages. This work includes retrospective analysis of 86 cases of patients treated with neoadjuvant chemotherapy according to the decision of the center's Functional Unit of Breast Cancer. All patients received neoadjuvant chemotherapy with a combination schedule of fluorouracil, epirubicin and cyclophosphamide. Chemotherapy is associated with multiple disabling side effects, knowing predictors of response to chemotherapy, we would treat those patients who derive most benefit from it, avoiding the treatment of the rest. We performed immunohistochemical analysis of the estrogen receptor, progesterone receptor, HER-2,Vimentin, cytokeratins 5/6 and Ki6. We correlated results with response, time to progression and survival. Moreover, from the immunohistochemical determination of estrogen and progesterone receptor, HER-2 and Ki67, tumors were classified in luminal A, luminal B, triple negative and HER-2 positive; and assessed the prognostic and predictive value of this classification. Huntingtin Interacting Protein 1 (HIP1) is a lipid-binding protein and clathrina inositol, which interacts with the actin-binding proteins, is considered the first component of the endocytosis machinery, playing an important role in trafficking of clathrina. In recent years, deregulation of endocytosis, have been associated with tumors. The change in the process of endocytosis due to alteration of HIP1, could therefore affect different processes in cancer progression and the response to chemotherapy. In this work we analyze the immunohistochemical expression of HIP1 and its relationship to chemotherapy response, time to progression and survival. Breast cancer susceptibility gene 1 (BRCA1), a gene that is part of the homologous recombination repair, has a role in DNA repair, cell cycle regulation, transcriptional control, the ubiquitination and apoptosis. It has been hypothesized in previous work that low levels of BRCA1 mRNA may predict a better response to chemotherapeutic agents whose mechanism is based on producing DNA alterations, such as anthracyclines or platinum compounds, and yet worse response to agents as taxanes. In our work we evaluated BRCA1 mRNA levels and their relation to the response to chemotherapy, time to progression and survival
Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer
Metastatic breast cancer (MBC) diagnosis in young women negatively impacts on quality of life (QoL) and daily activities, disrupting their life project and forcing them to face new psychosocial challenges. The recently published results on the improvement of the overall survival of pre- or perimenopausal women with hormone-receptor-positive, HER2-negative MBC treated with CDK4/6 inhibitors plus endocrine therapy, while preserving, and in some items improving their QoL, will change the landscape of the management of this patient population. Their extended survival and potential improvement in QoL will, therefore, modify their specific needs in terms of psychosocial support. The complexity of the care of young women with MBC is described herein, based on an extensive literature review. Further research about the specific psychosocial requirements of these women and a new multidisciplinary holistic approach is paramount to properly address their concerns and preferences. The communication with and support of their partners, parents and children is an important factor affecting the QoL of these patients. Altogether, a multidisciplinary care, open communication and personalized support is required to address the psychosocial implications of the new prognostic expectations on these patients with the incorporation of new targeted therapies